The CDMO Lonza has announced that it has strengthened its Advanced Synthesis offering to increase phase-appropriate support for the discovery and development of antibody-drug conjugates (ADCs) and other bioconjugates.
This new, strengthened offering is to include the full integration of the ADC technology platform, which the company says will now be offered as part of its Advanced Synthesis portfolio.
The platform includes the proprietary GlycoConnect antibody conjugation technology, the HydraSpace polar spacer technology and an expanding portfolio of toxSYN linker payloads.
These clinically validated, site-specific technologies were acquired by Lonza from Synaffix in 2023 and are designed to significantly improve the efficacy and tolerability of antibody-drug conjugates (ADCs).
These technologies have recently been expanded to include dual‑payload ADC technology, enabling the development of next‑generation ADCs to address tumour heterogeneity and drug-induced resistance.
The dual-payload approach enables the precise attachment of two complementary cytotoxic agents to a single antibody, allowing for controllable ratios of the payloads.
Lonza claims that, when combined with the company's expertise in development and manufacturing, this capability provides customers with access to innovative antibody-drug conjugate (ADC) designs within a fully integrated and scalable Contract Development and Manufacturing Organisation (CDMO) framework, from discovery through to clinical supply.
The Oss (NL) site has also expanded its capabilities through increased investment in laboratory infrastructure, enabling broader R&D activities across ADCs and emerging bioconjugate modalities, such as antibody-oligonucleotide conjugates, targeted lipid nanoparticles and protein-protein conjugates.
Recent growth includes the addition of new scientific roles and the continued expansion of laboratory capacity, reflecting sustained development of the site.
The Oss site now combines rapid small‑scale bioconjugate prototyping as a service with newly established scale‑up capabilities to deliver pilot toxicology material, while providing on‑site process and analytical development.
Jan Vertommen, Vice President, Commercial Development, Advanced Synthesis, Lonza, said: "Our recent advancements across Advanced Synthesis strengthen the support we provide to drug developers active in the field of ADCs and other bioconjugates."
The expansion of the Oss site further reinforces Lonza's global bioconjugate development and manufacturing network and underscores our dedication to continuously improving our offering and expertise in line with evolving customer and market needs.
